X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1137) 1137
pyrrolidinones - therapeutic use (916) 916
male (729) 729
animals (558) 558
female (537) 537
pyrrolidinones - pharmacology (504) 504
raltegravir potassium (476) 476
pharmacology & pharmacy (425) 425
hiv infections - drug therapy (404) 404
adult (397) 397
middle aged (384) 384
rats (238) 238
infectious diseases (206) 206
piracetam - therapeutic use (202) 202
aged (192) 192
mice (185) 185
raltegravir (185) 185
hiv integrase inhibitors - therapeutic use (183) 183
pyrrolidinones - adverse effects (183) 183
anti-hiv agents - therapeutic use (180) 180
pyrrolidinones - administration & dosage (179) 179
pyrrolidinones - chemistry (166) 166
treatment outcome (166) 166
hiv infections - virology (164) 164
dose-response relationship, drug (153) 153
immunology (138) 138
drug therapy, combination (136) 136
hiv-1 - drug effects (134) 134
hiv (131) 131
clinical trials as topic (127) 127
viral load (125) 125
adolescent (124) 124
pyrrolidinones - pharmacokinetics (124) 124
analysis (120) 120
double-blind method (119) 119
anticonvulsants - therapeutic use (107) 107
drug therapy (103) 103
microbiology (102) 102
neurosciences (99) 99
antiviral agents (96) 96
pharmacokinetics (96) 96
efficacy (95) 95
safety (95) 95
double-blind (93) 93
pyrrolidinones (93) 93
rolipram (93) 93
clinical neurology (92) 92
antiretroviral therapy (91) 91
epilepsy (90) 90
cd4 lymphocyte count (87) 87
virology (87) 87
drug interactions (85) 85
rats, sprague-dawley (81) 81
estrenes - pharmacology (80) 80
young adult (80) 80
child (79) 79
drug resistance, viral (79) 79
research (79) 79
hiv-1 (77) 77
disease models, animal (76) 76
time factors (74) 74
therapy (73) 73
hiv infection (70) 70
biochemistry & molecular biology (68) 68
oncology (68) 68
hiv integrase inhibitors - adverse effects (67) 67
hiv-1 - genetics (67) 67
care and treatment (65) 65
chemistry, medicinal (65) 65
drugs (65) 65
infection (65) 65
phosphodiesterase inhibitors - pharmacology (65) 65
health aspects (61) 61
in vitro techniques (61) 61
mutation (61) 61
aids/hiv (60) 60
hiv integrase inhibitors - pharmacology (60) 60
brivaracetam (59) 59
human immunodeficiency virus--hiv (59) 59
research article (59) 59
rats, wistar (57) 57
anti-hiv agents - adverse effects (55) 55
resistance (55) 55
anti-hiv agents - administration & dosage (54) 54
dosage and administration (54) 54
organic chemicals - therapeutic use (54) 54
epilepsy - drug therapy (53) 53
integrase (53) 53
medicine (53) 53
pyrrolidinones - metabolism (53) 53
rna, viral - blood (53) 53
cancer (51) 51
anti-hiv agents - pharmacology (50) 50
drug resistance (50) 50
hiv integrase - genetics (50) 50
cell line, tumor (49) 49
cells (49) 49
pyrrolidinones - blood (49) 49
aids (48) 48
antiepileptic drugs (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1373) 1373
German (60) 60
Russian (50) 50
French (35) 35
Italian (31) 31
Spanish (22) 22
Japanese (13) 13
Chinese (5) 5
Czech (5) 5
Polish (4) 4
Croatian (3) 3
Norwegian (2) 2
Portuguese (2) 2
Bulgarian (1) 1
Danish (1) 1
Dutch (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 6, pp. 1324 - 1334.e3
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity... 
Gastroenterology and Hepatology | Drug Interaction | HCV | Treatment | HIV | Liver Disease | ANTIRETROVIRAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | LIVER-DISEASE | SEXUAL TRANSMISSION | HEPATITIS-C VIRUS | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | PEGYLATED INTERFERON-ALPHA-2B | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Coinfection | Antiviral Agents - pharmacokinetics | HIV Infections - epidemiology | Humans | Hepatitis C, Chronic - etiology | Male | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Drug Interactions | Homosexuality, Male | Adenine - therapeutic use | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Raltegravir Potassium | Substance Abuse, Intravenous - complications | Emtricitabine | Liver Diseases - virology | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Liver Diseases - prevention & control | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Pyrrolidinones - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Proline - therapeutic use | HIV Infections - etiology | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Antiviral agents | Medical colleges | Care and treatment | Liver diseases | Comorbidity | Drug interactions | Mortality | Development and progression | Biological response modifiers | HIV (Viruses) | Hepatitis | Protease inhibitors | Proteases | Hepatitis C virus | Hepatitis C | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 01/2015, Volume 29, Issue 2, pp. 167 - 174
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 1, pp. 27 - 35
..., all of which are used in first-line regimens. In treatment-experienced patients on second-line regimens, use of ritonavir-boosted protease inhibitors is common. In a phase 2 study... 
Infectious Disease | INFECTIOUS DISEASES | DARUNAVIR-RITONAVIR | TREATMENT-NAIVE | DOSE-RESPONSE | COMBINATION THERAPY | TMC125 ETRAVIRINE | HIV-1-INFECTED PATIENTS | INFECTION | PLACEBO-CONTROLLED TRIAL | INTEGRASE INHIBITOR | SUBGROUP | Humans | Middle Aged | Male | RNA, Viral - blood | Alanine Transaminase - blood | Diarrhea - chemically induced | Viral Load | Oligopeptides - therapeutic use | Pyrrolidinones - administration & dosage | HIV Infections - immunology | Drug Therapy, Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Female | Raltegravir Potassium | Pyridines - therapeutic use | Anti-Retroviral Agents - therapeutic use | Pyrrolidinones - adverse effects | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Pyrrolidinones - therapeutic use | Treatment Outcome | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | HIV-1 - immunology | Quinolones - administration & dosage | Aspartate Aminotransferases - blood | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Lopinavir - therapeutic use | Antiviral agents | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | HIV patients | HIV (Viruses) | Anti-HIV agents
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 77 - 85
BACKGROUND:STARTMRK, a phase III noninferiority trial of raltegravir-based versus efavirenz-based therapy in treatment-naive patients, remained blinded until... 
raltegravir | HIV | STARTMRK | efavirenz | treatment naive | INFECTIOUS DISEASES | THERAPY | IMMUNOLOGY | HIV-1 INFECTION | SUBGROUP | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | HIV-1 | Oxazines | Humans | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Pyrrolidinones - therapeutic use | Benzoxazines - adverse effects | Treatment Outcome | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9692, pp. 796 - 806
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 06/2011, Volume 16, Issue 6, pp. 788 - 799
...) in many cancers, and its participation in multiple signal transduction pathways involved in malignant tumor growth, suggest a wide therapeutic potential for MET inhibition in human cancer... 
c‐MET | Epithelial growth factor inhibitor | Kinase receptor inhibitor | Hepatocyte growth factor | EGFR | C-MET | ONCOLOGY | RECEPTOR | c-MET | MUTATIONS | EXPRESSION | TUMORS | HGF/SF | Erlotinib Hydrochloride | Humans | Receptors, Growth Factor - antagonists & inhibitors | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Pyrrolidinones - administration & dosage | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Camptothecin - administration & dosage | Quinazolines - administration & dosage | Cetuximab | Camptothecin - analogs & derivatives | Camptothecin - therapeutic use | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Pyrrolidinones - therapeutic use | Enzyme Inhibitors - therapeutic use | Hepatocyte Growth Factor - metabolism | Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Quinolines - therapeutic use | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Clinical Pharmacology
Journal Article
Journal of Infection, ISSN 0163-4453, 2008, Volume 57, Issue 1, pp. 1 - 10
... to virological failure include adherence issues and previous use of mono/dual ARV therapy. Resistance may also develop as a random, positively selected phenomenon as HIV... 
Infectious Disease | Tipranavir | Darunavir | Maraviroc | Etravirine | Salvage therapy | Raltegravir | INFECTIOUS DISEASES | maraviroc | COMPLEX | EFFICACY | SAFETY | tipranavir | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | etravirine | PROTEASE INHIBITORS | THERAPY | DOUBLE-BLIND | RESISTANCE | darunavir | salvage therapy | rattegravir | EPIDEMIOLOGY | Triazoles - administration & dosage | Humans | Salvage Therapy | Cyclohexanes - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Cyclohexanes - therapeutic use | HIV Fusion Inhibitors - administration & dosage | Pyridazines - administration & dosage | Anti-HIV Agents - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | Raltegravir Potassium | Pyridazines - therapeutic use | CCR5 Receptor Antagonists | Pyridines - therapeutic use | Triazoles - therapeutic use | Pyridines - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Pyrrolidinones - therapeutic use | Treatment Outcome | Clinical Trials as Topic | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Pyrones - administration & dosage | HIV Fusion Inhibitors - therapeutic use | Sulfonamides - therapeutic use | HIV Integrase Inhibitors - therapeutic use | Pyrones - therapeutic use | HIV Infections - drug therapy | Sulfonamides - administration & dosage | Highly active antiretroviral therapy | Antiviral agents | Reverse transcriptase | Protease inhibitors | Proteases | HIV patients | HIV (Viruses) | Drug therapy | Drug resistance | HIV infection | Anti-HIV agents
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 3 - 14
[Display omitted] Marine sponges have consistently been the richest source of new marine natural products with unprecedented chemical scaffolds and potent... 
Porifera | Marine natural products | Drug discovery | ANDROGEN RECEPTOR | INOSITOL 5-PHOSPHATASE | PAIN SYNDROME | STRUCTURE ELUCIDATION | SHIP1 ACTIVATOR AQX-1125 | TARGETED DISRUPTION | IN-VITRO | CYTOTOXIC PEPTIDES | PHARMACOLOGY & PHARMACY | RESISTANT PROSTATE-CANCER | MARINE | Indans - adverse effects | Anti-Asthmatic Agents - therapeutic use | Humans | Drugs, Investigational - therapeutic use | Antineoplastic Agents - therapeutic use | Prodrugs - chemistry | Nonsteroidal Anti-Androgens - chemistry | Oligopeptides - therapeutic use | Nonsteroidal Anti-Androgens - therapeutic use | Sterols - adverse effects | Glycerol - analogs & derivatives | Porifera - chemistry | Benzhydryl Compounds - therapeutic use | Oligopeptides - chemistry | Anti-Asthmatic Agents - chemistry | Glycerol - therapeutic use | Indans - chemistry | Anti-Asthmatic Agents - pharmacology | Pyrrolidinones - adverse effects | Antimitotic Agents - adverse effects | Pyrrolidinones - therapeutic use | Antimitotic Agents - therapeutic use | Biological Products - isolation & purification | Biological Products - chemistry | Pyrrolidinones - isolation & purification | Cyclohexanols - therapeutic use | Oligopeptides - pharmacology | Anti-Asthmatic Agents - adverse effects | Cyclohexanols - adverse effects | Drugs, Investigational - adverse effects | Drugs, Investigational - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Oligopeptides - adverse effects | Indans - therapeutic use | Benzhydryl Compounds - chemistry | Drugs, Investigational - chemistry | Sterols - therapeutic use | Benzhydryl Compounds - adverse effects | Antineoplastic Agents - adverse effects | Cyclohexanols - chemistry | Nonsteroidal Anti-Androgens - adverse effects | Drug Design | Antineoplastic Agents - pharmacology | Glycerol - pharmacology | Aquatic Organisms - chemistry | Nonsteroidal Anti-Androgens - pharmacology | Sterols - pharmacology | Sterols - chemistry | Antineoplastic Agents - chemistry | Drug Discovery | Pyrrolidinones - chemistry | Prodrugs - adverse effects | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antimitotic Agents - pharmacology | Benzhydryl Compounds - pharmacology | Prodrugs - therapeutic use | Prodrugs - pharmacology | Antimitotic Agents - chemistry | Chemical oceanography | Index Medicus
Journal Article